We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
(Approval lapsed) DUPIXENT dupilumab 300mg solution for injection in pre-filled syringe (UK)
Section 19A approved medicine
(Approval lapsed) DUPIXENT dupilumab 300mg solution for injection in pre-filled syringe (UK)
Section 19A approval holder
Sanofi - Aventis Australia Pty Ltd ABN 31 008 558 807
Phone
1800 818 806
Approved until
Status
Expired
Medicines in short supply/unavailable
DUPIXENT dupilumab (rch) 300 mg/2 mL solution for injection pre-filled syringe with needle shield - ARTG 283127
Indication(s)
Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.
Dupixent is indicated as add on maintenance treatment in patients aged 12 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO).
Dupixent is indicated as maintenance therapy for oral corticosteroid dependent asthma.